Tesamorelin 2 mg (10‑vial kit)

Tesamorelin

Peptide / Biologic

GHRH analogue; growth\u2011hormone releasing peptide

FDA Approved for HIV Associated lipodystrophy under brand name Egrifta (various formulations including most recently Egrifta WR, approved March 25, 2025)
Classified as a prescription injectable drug for the approved indication; use for other purposes would be off‑label or unlicensed depending on jurisdiction

FDA Approved for HIV Associated lipodystrophy under brand name Egrifta (various formulations including most recently Egrifta WR, approved March 25, 2025)
Classified as a prescription injectable drug for the approved indication; use for other purposes would be off‑label or unlicensed depending on jurisdiction

GHRH analogue; growth\u2011hormone releasing peptide

Description

Tesamorelin is a synthetic analogue of human growth‑hormone releasing hormone (GHRH), modified to enhance stability (addition of a trans‑3‑hexenoic acid group). It stimulates the release of endogenous growth hormone (GH) via action on the pituitary, leading to increased IGF‑1 and changes in fat metabolism. The 2 mg vial supplied as lyophilised powder is typically sold for laboratory/research use only. Under the brand name (and earlier formulations such as Egrifta SV / Egrifta), tesamorelin is a U.S.‑approved injectable drug for the reduction of excess abdominal (visceral) fat in HIV-infected adult patients with lipodystrophy.

Bnefits

Stimulates endogenous growth hormone (GH) secretion via GHRH receptor activation
Reduction of visceral (abdominal) fat in HIV-associated lipodystrophy (FDA‑approved indication)
In research settings: potential modulation of body composition, fat distribution, and metabolic parameters via GH/IGF‑1 axis

Indications

Reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy (approved indication)
Not approved for weight loss, bodybuilding, anti‑aging, or general fat loss — other uses are off‑label or research only

Composition

Active substance: Tesamorelin (synthetic GHRH analogue; modified human GHRH 1‑44 with trans-3‑hexenoic acid)
Molecular formula: C₍₂₂₃₎H₍₃₇₀₎N₍₇₂₎O₍₆₉₎S (as per vendor/product data)
Molecular weight: ~5195.9 g/mol

Formulation

Lyophilised powder (white to off‑white) in 2 mg vials — intended to be reconstituted prior to injection

Packaging

10‑vial kit (each vial 2 mg lyophilised powder) — as supplied by research‑peptide vendors

Usage

Reconstitute with sterile bacteriostatic water (or as per vendor instructions) prior to subcutaneous injection — only under medical supervision if used as medication
For approved use (Egrifta): subcutaneous injection once daily, typically administered in the abdomen

Contraindications

Not to be used in patients with hypothalamic‑pituitary axis disruption (e.g., hypophysectomy, hypopituitarism, pituitary tumor/surgery, head irradiation or head trauma)
Active cancer
Allergy to tesamorelin or any ingredient in the formulation
Pregnancy or planning to become pregnant

Adverse Effects

Injection site reactions (erythema, pruritus, pain, swelling)
Arthralgia (joint pain)
Pain in extremity, myalgia (muscle pain)
Peripheral edema (swelling of hands, ankles, feet)
Potential increase in blood sugar/changes in glucose metabolism
Other less common effects: possible fluid retention, general tolerability issues (as per prescribing information)

Storage Conditions

Store vials refrigerated (per vendor guidance for lyophilised powder) — protect from light, moisture, and repeated freeze–thaw cycles
Once reconstituted, follow storage and usage instructions from manufacturer/physician (avoid prolonged storage, use sterile techniques)

Duration

As per prescribing physician\u2019s direction \u2014 in approved use (HIV lipodystrophy) continued as long as clinically indicated; for research use duration depends on study protocol